DDInter1657 DDInter867
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2
Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine.
Human adenovirus e serotype 4 strain cl-68578 antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Human adenovirus e serotype 4 strain cl-68578 antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Human adenovirus e serotype 4 strain cl-68578 antigen {u} may lead to a major life threatening interaction when taken with {v} Emapalumab
Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Human adenovirus e serotype 4 strain cl-68578 antigen may lead to a major life threatening interaction when taken with Emapalumab